A PHARMACEUTICALS business set up in Basingstoke more than 25 years ago has been valued at £31 billion after its board backed a takeover by a US firm.
Shire, which employs 5,300 people in 29 countries, will merge its operations with AbbVie, the maker of rheumatoid arthritis treatment Humira, as long as shareholders approve the tie-up later in the year.
Founded in 1986 by a group of five scientists, Shire is best known for its attention deficit disorder drugs. It is listed on the London Stock Exchange, has its tax base in Dublin and sells most of its products in North America.
In the UK, Shire employs 500 staff between sites in Basingstoke and Maidenhead, where work is carried out on some of the firm's biggest selling drugs such as treatments for Attention Deficit Hyperactivity Disorder (ADHD) and rare diseases such as Hunter Syndrome and Fabry disease.
AbbVie's pursuit of Shire started in early May, at the same time as AstraZeneca was fighting off interest worth £69 billion from drugs giant Pfizer.
The pharmaceuticals sector has seen a raft of deal-making activity in recent months as US companies look to Europe as a way to reduce their tax liabilities.
The Illinois-based firm said it plans to move its domicile to the UK in a move that would cut its corporate tax rate.
The company was formed in January 2013 after it was spun off from Abbott Laboratories. It employs around 25,000 people worldwide and markets medicines in more than 170 countries.
AbbVie had until today to confirm an offer for Shire, having increased its offer price from 4626p a share, or £27.2 billion, in May to a cash and shares proposal worth 5248p a share, equivalent to £30.9 billion.
Shire chairman Susan Kilsby said the price reflects the "substantial value" that the company has created for shareholders and also its future prospects.
She added: "We believe that the combined group represents an exciting fit of two complementary businesses.
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules hereComments are closed on this article